MORGAN STANLEY (MS) Stock News

Rosen Law Firm announces a securities class action lawsuit against Hims & Hers Health, Inc. for allegedly making false statements about data privacy practices and billing procedures. The lawsuit claims Hims shared consumer health information with third-party advertisers and charged for prescriptions immediately despite promising consultations with medical providers. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.

QEFA, a smart beta ETF launched in 2014 with $1.03 billion in assets, tracks the MSCI EAFE Factor Mix A-Series Index focusing on value, low volatility, and quality factors across developed markets. With a 0.30% expense ratio, 10.87% YTD return, and 15.44% one-year return, the fund offers medium risk (beta 0.68) with 638 holdings. However, the article suggests investors seeking outperformance should consider cheaper alternatives like IEFA (0.07% expense ratio) or EFA.

Robbins Geller announces a class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' health information with third-party advertising platforms and charging for prescriptions immediately after intake forms despite claiming personalized consultations. The FTC filed a lawsuit on July 29, 2026, leading to a 15% decline in Hims & Hers stock. Investors with substantial losses can seek lead plaintiff status before November 2, 2026.

Robbins LLP is reminding investors of a pending class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' sensitive health information with advertising platforms while claiming privacy protection, and engaging in deceptive billing practices. The FTC filed a lawsuit on July 29, 2026, which caused HIMS stock to decline 14.73%. Investors who purchased securities between August 4, 2025 and July 29, 2026 may be eligible to participate, with a lead plaintiff deadline of November 2, 2026.

Alignment Healthcare's stock plummeted 59% between July and October 2026 after CMS downgraded its California HMO plan (H3815) from 4.0 to 3.5 Star Rating, making it ineligible for quality bonus payments. The company faces investor scrutiny over allegedly misleading statements about its confidence in maintaining bonus eligibility, with management refusing to discuss Star Rating positioning in September before the downgrade was publicly disclosed.

A class action securities fraud lawsuit has been filed against Hims & Hers Health, Inc. following an FTC lawsuit alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file a lead plaintiff motion.

nuVizz has been recognized as an Accelerator in Nucleus Research's 2026 Transportation Management Value Matrix for its specialized last-mile delivery TMS platform. The platform orchestrates complex delivery networks across internal fleets, contracted carriers, and delivery partners through a unified operating environment, addressing fragmentation issues in last-mile logistics.

The Fidelity MSCI Industrials Index ETF (FIDU) is a passively managed ETF offering broad exposure to the industrials sector with a low expense ratio of 0.08%, $2.2 billion in assets, and a Zacks ETF Rank of 2 (Buy). The fund has returned 9.18% year-to-date and 11.27% over the past year, with a beta of 1.03 and 368 holdings providing diversification.

Rosen Law Firm has filed securities class action lawsuits against multiple companies. The primary case involves Hims & Hers Health, Inc., alleging the company made false statements about data privacy, charged consumers for prescriptions without proper consultation, and failed to disclose regulatory scrutiny. The firm is seeking lead plaintiffs with a November 2, 2026 deadline. Similar lawsuits have been filed against Papa John's International and Millrose Properties.

A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false statements and failing to disclose that it shares consumers' health information with third-party advertising platforms and charges for prescriptions immediately after intake forms are submitted. The FTC, California, and Utah filed a separate lawsuit on July 29, 2026, resulting in a 14.73% stock price decline.

MSCI is expected to report Q3 2026 earnings of $5.00 per share (up 11.9% YoY) with revenues of $879.98 million (up 10.9% YoY) on October 20. The company has a positive Earnings ESP of +0.26% combined with a Zacks Rank #3, suggesting a likely earnings beat. MSCI has beaten consensus EPS estimates in all four of the last quarters.

Microsoft has been heavily searched on Zacks.com and has outperformed the broader market with an 8% return over the past month. The company is expected to post 14% year-over-year earnings growth for the current quarter and 18.3% growth for the next fiscal year, with strong revenue growth projections of 16.6-18.4%. However, Microsoft received a Zacks Rank #3 (Hold) rating and a D valuation grade, indicating it is trading at a premium to peers and may perform in line with the broader market in the near term.

PABU is a smart beta ETF with $2.5 billion in assets that tracks climate-aligned U.S. stocks. It has low expenses (0.10%), strong year-to-date performance (+11.29%), and heavy tech exposure (55.5%). The fund offers diversified exposure with 91 holdings, though it carries slightly higher volatility (beta 1.07) compared to traditional market-cap weighted alternatives.

The Fidelity MSCI Consumer Staples Index ETF (FSTA) offers low-cost, diversified exposure to the consumer staples sector with a 0.08% expense ratio and $1.39 billion in assets. The ETF has gained 8.98% year-to-date with a beta of 0.49, making it a medium-risk option. It carries a Zacks ETF Rank of 3 (Hold) and is compared to alternatives like Vanguard Consumer Staples Index Fund (VDC) and State Street Consumer Staples Select Sector SPDR ETF (XLP).

The Fidelity MSCI Consumer Discretionary Index ETF (FDIS) is a passively managed fund with low costs (0.08% expense ratio) and $1.63 billion in assets. However, it received a Zacks ETF Rank of 4 (Sell) and is not recommended for investors seeking consumer discretionary exposure. The fund has underperformed year-to-date, declining 3.26%, with a beta of 1.26 indicating medium risk. Better alternatives include Vanguard Consumer Discretionary Index Fund (VCR) and State Street Consumer Discretionary Select Sector SPDR ETF (XLY).

Rosen Law Firm is encouraging investors who purchased Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false and misleading statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.

Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company deceptively shared consumers' health data with third-party advertising platforms like Meta and Snap, and violated billing regulations by charging for prescriptions before medical consultations. The stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value.

Strategy Inc. shares rallied 60% over three months, outperforming Bitcoin miners Riot Platforms and CleanSpark, driven by its expanding Bitcoin treasury which reached 848,000 coins. However, the company's extremely high forward P/S ratio of 114.08X and potential share dilution raise valuation concerns, prompting analysts to recommend patience despite improved financial flexibility and cash reserves of $4.88 billion.

The Fidelity MSCI Utilities Index ETF (FUTY) is a low-cost passively managed fund with a 0.08% expense ratio and $2.18 billion in assets. However, it has received a Zacks ETF Rank of 4 (Sell) and is not recommended for investors seeking utilities exposure. The fund has underperformed year-to-date, declining 1.81%, with better alternatives available such as Vanguard Utilities Index Fund ETF Shares (VPU) and State Street Utilities Select Sector SPDR ETF (XLU).

A comprehensive market report on China's stretchers and cots sector forecasts growth through 2033 across ambulance cots, emergency stretchers, manual and motorized transport segments. The report provides historical data from 2018, competitive analysis of key players, and strategic insights for market entry and investment decisions in the medical transport equipment sector.

Rosen Law Firm has filed securities class action lawsuits against Hims & Hers Health, Duolingo, and Ardelyx. The Hims lawsuit alleges the company made false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased securities during specified class periods are encouraged to join the litigation before the November 2, 2026 lead plaintiff deadline.

Morgan Stanley stock declined 1.2% to $187.44, underperforming the S&P 500's 0.47% loss. The stock has fallen 11.91% over the past month, significantly outpacing the Finance sector's 5.13% decline. Ahead of its October 14 earnings report, analysts project Q3 EPS of $2.88 (up 2.86% YoY) and revenue of $19.71 billion (up 8.15% YoY). Morgan Stanley holds a Zacks Rank #3 (Hold) with a Forward P/E of 14.96, trading at a premium to its industry average of 13.08.

Morgan Stanley is expected to report Q3 2026 earnings of $2.88 per share with 8.2% revenue growth, but recent analyst revisions and a negative Earnings ESP of -0.20% suggest limited upside surprise potential. Similarly, Goldman Sachs faces headwinds with an -8.71% Earnings ESP despite expected 9% EPS growth, making both stocks difficult earnings-beat candidates despite their strong historical performance.

Novartis will present Phase III REMODEL-1/-2 trial results for remibrutinib, an oral BTK inhibitor for relapsing multiple sclerosis, at MSToronto2026. The company will also showcase expanded evidence for Kesimpta (ofatumumab) across multiple studies including pediatric MS, treatment-naive patients, and pregnancy/breastfeeding outcomes. An investor call will follow the remibrutinib data presentation.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026.

Quantum BioPharma has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in progressive multiple sclerosis. The agreement marks a significant milestone following FDA clearance and represents the initiation of formal study start-up activities.

QUAL is a smart beta ETF launched in 2013 that tracks the MSCI USA Sector Neutral Quality Index with $48.59 billion in assets. It offers broad exposure to U.S. large and mid-cap stocks with a low 0.15% expense ratio and 0.84% dividend yield. The fund is heavily weighted toward Information Technology (40.1%) with top holdings including Microsoft, Apple, and Nvidia. With a beta of 1.00 and 14.20% standard deviation, it represents a medium-risk option that has returned 14.37% year-to-date as of October 2026.

Rosen Law Firm is soliciting investors who purchased securities of Hims & Hers Health, Inc. between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.

YieldMax® announced weekly distributions for three Performance & Distribution Target 25 ETFs tracking MSTR, NVDA, and TSLA, with distribution rates of 25.00% and 30-day SEC yields ranging from 0.41% to 3.11%. The distributions are ex-dated October 6, 2026 and payable October 7, 2026. The article emphasizes that distributions are variable and not guaranteed, with significant risks including call writing strategy limitations and single-issuer concentration.

A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false and misleading statements regarding consumer data sharing with third-party advertising platforms, charging for prescriptions before medical consultations, and failing to disclose regulatory scrutiny and potential penalties. The lead plaintiff deadline is November 2, 2026.